4 Corners Pharmacy Xenical. orlistat weight loss
Search . . . . . . . .
 
 
Other Sections  
 
 
 

Xenical Articles  Xenical Articles


Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.

 

 Xenical: Prices and Ordering Information

Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, Zavoral JH, Aronne LJ

University of Colorado Health Sciences Center, Denver, USA.

1 : Am J Clin Nutr 1999 Jun;69(6):1108-16

BACKGROUND:

Long-term maintenance of weight loss remains a therapeutic challenge in obesity treatment.

OBJECTIVE:

This multicenter, double-blind, placebo-controlled study was designed to test the hypothesis that orlistat, a gastrointestinal lipase inhibitor, is significantly more effective than a placebo in preventing weight regain.

DESIGN:

Obese subjects who lost > or = 8% of their initial body weight during a 6-mo lead-in of a prescribed hypoenergetic diet (4180-kJ/d deficit) with no adjunctive pharmacotherapy were randomly assigned to receive placebo, 30 mg orlistat, 60 mg orlistat, or 120 mg orlistat 3 times daily for 1 y in combination with a maintenance diet to help prevent weight regain. Of 1313 recruited subjects [body mass index (in kg/m2): 28-43], 729 subjects lost > or =8% of their initial body weight during the 6-mo weight-loss lead-in period and were enrolled in the double-blind phase.

RESULTS:

After 1 y, subjects treated with 120 mg orlistat 3 times daily regained less weight than did placebo-treated subjects (32.8 4.5% compared with 58.7 5.8% regain of lost weight; P < 0.001). Moreover, more subjects in the 120-mg orlistat group than in the placebo group regained < or = 25% of lost weight (47.5% of subjects compared with 29.9%). In addition, orlistat treatment (120 mg 3 times daily) was associated with significantly greater reductions in total and LDL-cholesterol concentrations than was placebo (P < 0.001).

CONCLUSION:

The use of orlistat during periods of attempted weight maintenance minimizes weight readjustment and facilitates long-term improvement in obesity-related disease risk factors.

Publication Types:

Clinical trial

Multicenter study

Randomized controlled trial

Comments:

Comment in: Am J Clin Nutr 1999 Jun;69(6):1059-60

Comment in: Am J Clin Nutr 1999 Jun;69(6):1061-3



 

 

4 Corners Weight Loss Pharmacy

About the Pharmacy
Contact
FAQ
Privacy Policy

View Your Shopping Cart

Products

XenicalXenical

Non Prescription
Supplements

Chitosan
Fat Metaboliser
Super Fat Burners
Citrimax
Evening Primrose Oil
 

Information

Xenical
Chitosan
L-Carnitine
HCA
Weight Loss
Supplements
 

Other Centers..

 Anti Depressants
 Arthritis
 Asthma Allergy
 Birth Control
 Diabetes
 Digestive
 General Medications
 Generics
 Infections
 Hair Loss
 Heart Health
 Hormones
 Mens Health
 Neurological
 Pain Control
 Pet Care
 Skin Care
 Stop Smoking
 Transgender
 Weight Loss